Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

LYB001

From Wikipedia, the free encyclopedia
Vaccine candidate against COVID-19

Pharmaceutical compound
LYB001
Vaccine description
TargetSARS-CoV-2
Vaccine typeVirus-like particles
Clinical data
Routes of
administration
Intramuscular
Part ofa series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
virus iconCOVID-19 portal

LYB001 is aCOVID-19 vaccine candidate developed by Yantai Patronus Biotech Co., Ltd.[1][2][3][4]

It was found to be safe and well tolerated.[5]

References

[edit]
  1. ^"Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy adults: a randomized, double blinded, placebo-controlled phase I trial".chictr.org.cn. Chinese Clinical Trial Registry. Retrieved15 October 2021.
  2. ^"A Phase I Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001".ClinicalTrials.gov. 18 November 2021. NCT05125926. Retrieved18 November 2021.
  3. ^"Immunogenicity and safety of a SARS-CoV-2 Vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial".chictr.org.cn. Chinese Clinical Trial Registry. Retrieved15 October 2021.
  4. ^"Phase II and III Trial of a SARS-CoV-2 Vaccine LYB001".ClinicalTrials.gov. 30 November 2021. NCT05137444. Retrieved30 November 2021.
  5. ^Tang R, Zeng Y, Zhou Y, Liang Q, Kang W, Yang Z, et al. (2 May 2024)."Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study".Expert Review of Vaccines.23 (1):498–509.doi:10.1080/14760584.2024.2337051.PMID 38695310.
logo
Scholia has a profile forLYB001(Q110269779).
Development
Classes
Administration
Vaccines
Bacterial
Viral
Protozoan
Helminthiasis
Other
Inventors/
researchers
Controversy
Related
Pre-pandemic
2020
2021
2022
2023
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
By location
Others
Data (templates)
Global
Africa
Americas
Asia
Europe
Oceania
Others
Portals:
Stub icon

This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it.

Stub icon

This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=LYB001&oldid=1290414081"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp